Market Overview:
The global mild-to-moderate atopic dermatitis treatment market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of atopic dermatitis, rising awareness about available treatments, and growing demand for better and more effective therapies. The global mild-to-moderate atopic dermatitis treatment market is segmented on the basis of type of treatment into radiation therapy and drug therapy. The drug therapy segment is further subsegmented into topical corticosteroids, calcineurin inhibitors, immunosuppressants, pimecrolimus cream 1%, tacrolimus ointment 0.1%, methotrexate tablets 2.5 mg/week orally (maximum dose 25 mg/week), azathioprine tablets 50 mg orally once daily (maximum dose 100 mg per day), cyclosporine capsules 25mg orally twice daily (maximum dose 200mg per day), mycophenolate mofetil capsules 500mg orally twice daily (maximum dose 3 g per day) and others such as leflunomide 10–20 mg/day oral tablet). The radiation therapy segment is further subsegmented into ultraviolet B phototherapy, broadband ultraviolet A phototherapy and narrowband ultraviolet B phototherapy.
Product Definition:
Mild-to-moderate atopic dermatitis is a skin condition that causes dry, itchy skin. Treatment includes using moisturizers and steroid creams to reduce inflammation. It is important to treat mild-to-moderate atopic dermatitis because it can lead to more severe symptoms if left untreated.
Radiation Treatment:
Atopic dermatitis is a common, chronic, and incurable condition affecting the skin of infants and adults. The disease has three stages-stage one being mild-to-moderate, stage two being moderate to severe which may require systemic therapy such as antihistamines or corticosteroids and stage three being severe with lifethreatening complications requiring emergency treatment such as epinephrine (Adrenaline) injection.
Drug Treatment:
Drug treatment and it's usage in mild-to-moderate atopic dermatitis (AD) treatment market is expected to grow rapidly during the forecast period. The major factor that propels the growth of this market includes increasing prevalence of AD. According to National Institute for Health and Care Excellence (NICE), it was estimated that around 1 in 5 children suffer from AD, which leads to huge economic burden on society due to loss of productivity caused by illness.
Application Insights:
The others segment held the largest share of 60.0% in 2017. Others application category includes sensitive skin, eczema, and others ADM patients who have not been able to find suitable treatment options at local pharmacies or hospitals due to their location or financial constraints. The mild-to-moderate atopic dermatitis treatment market is anticipated to offer significant growth opportunities for online pharmacies as well as hospital/retail pharmacies located outside the major cities in countries with a population of less than 5 million people such as India and China due to high unmet needs of patients suffering from AD across the globe.
AD affects around 50 million individuals in North America region alone which can be treated by topical steroids applied twice daily for 2 weeks followed by once a day maintenance therapy (if required).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing awareness about various treatment options, availability of highly advanced technology and presence of key manufacturers in this region. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure and growing patient awareness about available treatments for moderate-to-severe AD. Moreover, an increase in number of international shipments from countries like Japan and China will boost regional growth further. In addition, favorable regulatory policies implemented by FDA are also contributing towards increased sales volume of products across this region.
Growth Factors:
- Increasing prevalence of atopic dermatitis
- Growing awareness about atopic dermatitis and its treatment options
- Rising demand for better and more effective atopic dermatitis treatments
- Availability of new and innovative atopic dermatitis treatments
- Growing number of clinical studies on atopic dermatitis
Scope Of The Report
Report Attributes
Report Details
Report Title
Mild-to-Moderate Atopic Dermatitis Treatment Market Research Report
By Type
Radiation Treatment, Drug Treatment
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Novartis, Pfizer, Sanofi, Anacor Pharmaceuticals, Astellas Pharma, Meda Pharmaceuticals, Regeneron Pharmaceuticals, Bausch Health
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Mild-to-Moderate Atopic Dermatitis Treatment Market Report Segments:
The global Mild-to-Moderate Atopic Dermatitis Treatment market is segmented on the basis of:
Types
Radiation Treatment, Drug Treatment
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Sanofi
- Anacor Pharmaceuticals
- Astellas Pharma
- Meda Pharmaceuticals
- Regeneron Pharmaceuticals
- Bausch Health
Highlights of The Mild-to-Moderate Atopic Dermatitis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Radiation Treatment
- Drug Treatment
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mild-to-Moderate Atopic Dermatitis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best Mild-to-Moderate Atopic Dermatitis treatment will vary depending on the individual's symptoms and overall health. However, some possible Mild-to-Moderate Atopic Dermatitis treatments include: • Overthecounter topical medications such as corticosteroids or moisturizers • Prescription medications such as azathioprine or methotrexate • Injections of immunosuppressants such as cyclosporine A • Surgery to remove skin lesions
Some of the major players in the mild-to-moderate atopic dermatitis treatment market are Novartis, Pfizer, Sanofi, Anacor Pharmaceuticals, Astellas Pharma, Meda Pharmaceuticals, Regeneron Pharmaceuticals, Bausch Health.
The mild-to-moderate atopic dermatitis treatment market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mild-to-Moderate Atopic Dermatitis Treatment Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Mild-to-Moderate Atopic Dermatitis Treatment Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Mild-to-Moderate Atopic Dermatitis Treatment Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Mild-to-Moderate Atopic Dermatitis Treatment Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Mild-to-Moderate Atopic Dermatitis Treatment Market Size & Forecast, 2020-2028 4.5.1 Mild-to-Moderate Atopic Dermatitis Treatment Market Size and Y-o-Y Growth 4.5.2 Mild-to-Moderate Atopic Dermatitis Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Radiation Treatment
5.2.2 Drug Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mild-to-Moderate Atopic Dermatitis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mild-to-Moderate Atopic Dermatitis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Radiation Treatment
9.6.2 Drug Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Radiation Treatment
10.6.2 Drug Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Radiation Treatment
11.6.2 Drug Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Radiation Treatment
12.6.2 Drug Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Radiation Treatment
13.6.2 Drug Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mild-to-Moderate Atopic Dermatitis Treatment Market: Competitive Dashboard
14.2 Global Mild-to-Moderate Atopic Dermatitis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 Sanofi
14.3.4 Anacor Pharmaceuticals
14.3.5 Astellas Pharma
14.3.6 Meda Pharmaceuticals
14.3.7 Regeneron Pharmaceuticals
14.3.8 Bausch Health